Mnemosyne Pharmaceuticals Announces Appointment of New CSO Timothy Piser, Ph.D., to Lead …

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mnemosyne Pharmaceuticals is pleased to announce the recruitment of 20-year neuroscience R&D veteran Timothy Piser, Ph.D., to the leadership team. He will serve as Chief Scientific Officer (CSO). In addition, effective immediately, Mnemosyne has changed its name to Luc Therapeutics, Inc. (pronounced ‘Luke’) to better reflect the Company’s ongoing corporate evolution, and its overall synaptic plasticity-oriented drug development strategy. The new Luc Therapeutics will be headquartered in Cambridge, MA. “Changing our name to Luc Therapeutics reflects the tremendous progress we have made to focus our discovery capabilities on areas where NMDA receptor modulation offers the most tractable path to potential therapeutics for patients,” said Vanessa King, Ph.D., Luc’s President and CEO. “‘Luc’ references the English word lucidity and the Italian word luce; our intention is to develop therapeutics…


Link to Full Article: Mnemosyne Pharmaceuticals Announces Appointment of New CSO Timothy Piser, Ph.D., to Lead …